Evidence map›Paper›PMID 32346612›Full record

ArticleMolecular therapy oncolytics2020

Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy.

Amin Aalipour, Fabrice Le Boeuf, Matthew Tang, Surya Murty, Federico Simonetta, Alexander X Lozano, Travis M Shaffer, John C Bell, Sanjiv S Gambhir

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Engaging T cells for cleanup.Frontiers in immunology · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amin AalipourDepartment of Bioengineering, Stanford University School of Medicine, Stanford, CA 94305, USA.
Fabrice Le BoeufCancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Matthew TangCancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Surya MurtyDepartment of Bioengineering, Stanford University School of Medicine, Stanford, CA 94305, USA.
Federico SimonettaDivision of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alexander X LozanoDepartment of Materials Science and Engineering, Stanford University, Stanford, CA 94305, USA.
Travis M ShafferMolecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA 94305, USA.
John C BellCancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Sanjiv S GambhirDepartment of Bioengineering, Stanford University School of Medicine, Stanford, CA 94305, USA.

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
SYNTHETIC GENE CIRCUITS FOR MONITORING T-CELL EXHAUSTIONF30CA236339 · NCI · STANFORD UNIVERSITY · PI AALIPOUR, AMIN · 2019 to 2020
$70k
NCI NIH HHS F30 CA236339
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy has had limited efficacy for solid tumors, largely due to a lack of selectively and highly expressed surface antigens. To avoid reliance on a tumor's endogenous antigens, here we describe a method of tumor-selective delivery of surface antigens using an oncolytic virus to enable a generalizable CAR T cell therapy. Using CD19 as our proof of concept, we engineered a thymidine kinase-disrupted vaccinia virus to selectively deliver CD19 to malignant cells, and thus demonstrated potentiation of CD19 CAR T cell activity against two tumor types

Indexed as

CAR T cellscell therapychimeric antigen receptorcombination immunotherapyimmunotherapyoncolytic virussolid tumorsynthetic immunologytumor engineeringvaccinia virus

Identifiers

PMID32346612
PMCPMC7183102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.